Neoadjuvant therapy that combines abiraterone acetate plus prednisone (AAP) and leuprolide prior to radical prostatectomy significantly reduces tumor size in men with high-risk localized prostate cancer (PCa) and may decrease the risk of biochemical recurrence compared with leuprolide alone, according to a new study.